Gilead Sciences 2015 Annual Report Download - page 5

HEMATOLOGY / ONCOLOGY
PHASE 3
IDELALISIB (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: FRONTLINE AND RELAPSED REFRACTORY CLL (CHRONIC
LYMPHOCYTIC LEUKEMIA)
IDELALISIB (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: RELAPSED REFRACTORY iNHL (INDOLENT NON-HODGKIN’S
LYMPHOMA)
MOMELOTINIB (JAK INHIBITOR)
POTENTIAL INDICATION: MYELOFIBROSIS
MOMELOTINIB (JAK INHIBITOR)
POTENTIAL INDICATION: PANCREATIC CANCER
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: GASTRIC CANCER
PHASE 2
IDELALISIB (PI3K DELTA INHIBITOR)
POTENTIAL INDICATION: FRONTLINE iNHL (INDOLENT NON-HODGKIN’S
LYMPHOMA)
ENTOSPLETINIB (SYK INHIBITOR)
POTENTIAL INDICATION: HEMATOLOGICAL MALIGNANCIES
PHASE 1
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: SOLID TUMORS
GS-4059 (BTK INHIBITOR)
POTENTIAL INDICATION: B-CELL MALIGNANCIES
GS-5829 (BET INHIBITOR)
POTENTIAL INDICATION: SOLID TUMORS
INFLAMMATION / RESPIRATORY
PHASE 2/3
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: ULCERATIVE COLITIS
PHASE 2
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: CROHN’S DISEASE
PRESATOVIR (FUSION INHIBITOR)
POTENTIAL INDICATION: RESPIRATORY SYNCYTIAL VIRUS
FILGOTINIB (JAK1 INHIBITOR)
POTENTIAL INDICATION: RHEUMATOID ARTHRITIS
FILGOTINIB (JAK1 INHIBITOR)
POTENTIAL INDICATION: CROHN’S DISEASE
PHASE 1
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: COPD
GS-5745 (ANTI-MMP9 MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: RHEUMATOID ARTHRITIS
GS-9876 (SYK INHIBITOR)
POTENTIAL INDICATION: RHEUMATOID ARTHRITIS
OTHER
PHASE 2
GS-4997 (ASK-1 INHIBITOR)
POTENTIAL INDICATION: DIABETIC NEPHROPATHY
PHASE 1
GS-5734 (NUC INHIBITIOR)
POTENTIAL INDICATION: EBOLA VIRUS INFECTION
HIV / AIDS
U.S. AND EU REGULATORY SUBMISSION
F/TAF (EMTRICITABINE/TENOFOVIR ALAFENAMIDE)
POTENTIAL INDICATION: HIV/AIDS
EU REGULATORY SUBMISSION
STR OF R/F/TAF (RILPIVIRINE/EMTRICITABINE/TENOFOVIR ALAFENAMIDE)
POTENTIAL INDICATION: HIV/AIDS
PHASE 3
GS-9883/F/FAF (NON-BOOSTED INTEGRASE INHIBITOR/EMTRICITABINE/
TENOFOVIR ALAFENAMIDE)
POTENTIAL INDICATION: HIV/AIDS
PHASE 1
GS-9620 (TLR-7 AGONIST)
POTENTIAL INDICATION: HIV/AIDS
LIVER DISEASES
U.S. AND EU REGULATORY SUBMISSION
STR OF SOFOSBUVIR/VELPATASVIR (PAN-GENOTYPIC NS5B/NS5A INHIBITORS)
POTENTIAL INDICATION: CHRONIC HCV INFECTION
U.S. AND EU REGULATORY SUBMISSION
TAF (NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR)
POTENTIAL INDICATION: CHRONIC HBV INFECTION
PHASE 3
SOFOSBUVIR, VELPATASVIR AND GS-9857
(PAN-GENOTYPIC NS3 PROTEASE INHIBITOR)
POTENTIAL INDICATION: CHRONIC HCV INFECTION
PHASE 2
GS-4774 (TARMOGEN T CELL IMMUNITY STIMULATOR)
POTENTIAL INDICATION: CHRONIC HBV INFECTION
GS-9620 (TLR-7 AGONIST)
POTENTIAL INDICATION: CHRONIC HBV INFECTION
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: NASH
SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: PRIMARY SCLEROSING CHOLANGITIS
GS-4997 (ASK-1 INHIBITOR)
POTENTIAL INDICATION: NASH
GS-4997 (ASK-1 INHIBITOR) + SIMTUZUMAB (MONOCLONAL ANTIBODY)
POTENTIAL INDICATION: NASH
PHASE 1
GS-9674 (FXR AGONIST)
POTENTIAL INDICATION: NASH
CARDIOVASCULAR
PHASE 3
ELECLAZINE (LATE SODIUM CURRENT INHIBITOR)
POTENTIAL INDICATION: LONG QT-3 SYNDROME
PHASE 2
ELECLAZINE (LATE SODIUM CURRENT INHIBITOR)
POTENTIAL INDICATION: HYPERTROPHIC CARDIOMYOPATHY
ELECLAZINE (LATE SODIUM CURRENT INHIBITOR)
POTENTIAL INDICATION: VENTRICULAR TACHYCARDIA/VENTRICULAR
FIBRILLATION
GS-4997 (ASK-1 INHIBITOR)
POTENTIAL INDICATION: PULMONARY ARTERIAL HYPERTENSION
PIPELINE
Pipeline current as of 3/7/16
CARDIOVASCULAR
LETAIRIS®
AMBRISENTAN 5 MG AND 10 MG
PULMONARY ARTERIAL HYPERTENSION
(WHO GROUP 1)
GLAXOSMITHKLINE INC. (OUTSIDE THE U.S.)
MARKETED AS VOLIBRIS® (OUTSIDE THE U.S.)
LEXISCAN®
REGADENOSON INJECTION 0.4 MG
CORONARY VASODILATION
ASTELLAS PHARMA INC. (U.S., CANADA)
RAPIDSCAN (EUROPE AND SELECT OTHER
MARKETS)
RANEXA®
RANOLAZINE 500 MG AND 1000 MG
CHRONIC ANGINA
MENARINI GROUP (EUROPE AND SELECT
OTHER MARKETS)
HEMATOLOGY/
ONCOLOGY
ZYDELIG®
IDELALISIB 150 MG
RELAPSED FOLLICULAR B-CELL NON-HODGKIN
LYMPHOMA
RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
RELAPSED SMALL LYMPHOCYTIC LYMPHOMA
OTHER
AMBISOME®
AMPHOTERICIN B LIPOSOME FOR INJECTION
50 MG/VIAL
SEVERE FUNGAL INFECTIONS
ASTELLAS PHARMA INC. (U.S., CANADA)
SUMITOMO DAINIPPON PHARMA CO., LTD.
(JAPAN)
MACUGEN®
PEGAPTANIB SODIUM INJECTION 0.3 MG
NEOVASCULAR (WET) AGE-RELATED
MACULAR DEGENERATION
EYETECH, INC. (U.S.)
PFIZER INC. (OUTSIDE THE U.S.)
HIV/AIDS
ATRIPLA®
EFAVIRENZ 600 MG/EMTRICITABINE
200 MG/TENOFOVIR DISOPROXIL
FUMARATE 300 MG
HIV/AIDS
BRISTOL-MYERS SQUIBB COMPANY
(U.S., WESTERN EUROPE, CANADA)
MERCK & CO., INC. (REST OF WORLD)
COMPLERA®
EMTRICITABINE 200 MG/RILPIVIRINE 25 MG/
TENOFOVIR DISOPROXIL FUMARATE 300 MG
HIV/AIDS
JANSSEN SCIENCES IRELAND UC
(SELECT MARKETS)
MARKETED AS EVIPLERA® IN EUROPE
EMTRIVA®
EMTRICITABINE 200 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
GENVOYA®
ELVITEGRAVIR 150 MG/COBICISTAT 150 MG/
EMTRICITABINE 200 MG/TENOFOVIR
ALAFENAMIDE 10 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
ODEFSEY®
EMTRICITABINE 200 MG/RILPIVIRINE 25 MG/
TENOFOVIR ALAFENAMIDE 25 MG
HIV/AIDS
JANSSEN SCIENCES IRELAND UC
(SELECT MARKETS)
STRIBILD®
ELVITEGRAVIR 150MG/COBICISTAT 150MG/
EMTRICITABINE 200MG/TENOFOVIR
DISOPROXIL FUMARATE 300MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
TRUVADA®
EMTRICITABINE 200 MG/TENOFOVIR DISOPROXIL
FUMARATE 300 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
TYBOST®
COBICISTAT 150 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
HIV/AIDS (CONT.)
VIREAD®
TENOFOVIR DISOPROXIL FUMARATE 300 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
VITEKTA®
ELVITEGRAVIR 85 MG AND 150 MG
HIV/AIDS
JAPAN TOBACCO INC. (JAPAN)
LIVER DISEASES
HARVONI®
LEDIPASVIR 90 MG/SOFOSBUVIR 400 MG
CHRONIC HEPATITIS C
HEPSERA®
ADEFOVIR DIPIVOXIL 10 MG
CHRONIC HEPATITIS B
GLAXOSMITHKLINE INC.
(CHINA, JAPAN, SAUDI ARABIA)
SOVALDI®
SOFOSBUVIR 400 MG
CHRONIC HEPATITIS C
VIREAD®
TENOFOVIR DISOPROXIL FUMARATE 300 MG
CHRONIC HEPATITIS B
GLAXOSMITHKLINE INC. (CHINA AND JAPAN)
INFLAMMATION/
RESPIRATORY
CAYSTON®
AZTREONAM FOR INHALATION SOLUTION
75 MG/VIAL
CYSTIC FIBROSIS, PSEUDOMONAS AERUGINOSA
TAMIFLU®
OSELTAMIVIR PHOSPHATE 75 MG
INFLUENZA A & B
F. HOFFMANN-LA ROCHE LTD
(WORLDWIDE)
Images shown do not represent actual size.
For other dosage strengths see full prescribing information.
Medicines current as of 3/7/16
MEDICINES
76